GSK3A and Down syndrome: Albeit dual inhibition of GSK3α,β paralogs has been hampered as a treatment strategy in clinical trials in disorders with normal β-cat levels due to β-cat stabilization and the potential for aberrant cell proliferation, increasing β-cat levels is the goal for CTNNB1 syndrome where β-cat levels are reduced by pathogenic heterozygous loss-of-function variants.